State pension funds are looking at a $1 trillion shortfall in what they owe workers in benefits, according to new data from The Pew Charitable Trusts.
El-Erian made his comments ahead of Fed Chair Janet Yellen's speech, scheduled for Friday morning in Jackson Hole, Wyoming.
Pharmaceutical company Mylan has reduced the cost of EpiPens for some people — but at the end of the day, its CEO told CNBC she has a business to run.
Did you predict that oil would bounce in 2016? Nice! Did you attempt to cash in by buying the biggest oil ETF? Uh-oh.
The savings came under a program where health providers coordinate care for 7.7 million Medicare beneficiaries.
Hillary Clinton and Donald Trump clashed on Thursday, accusing each other of posing a threat to the interests of blacks and Latinos.
Hillary Clinton has opened up a 10-point national lead over Donald Trump, a new poll suggests.
A Donald Trump surrogate blasts a new Hillary Clinton campaign ad that tied Trump's campaign to racist hate groups.
Under pressure, Mylan plans to boost access to its EpiPen Auto-Injector by expanding existing programs for patients who are facing higher costs.
There needs to be more transparency in drug pricing, and Mylan still has a lot of questions to answer, Sen. Charles Grassley said Thursday.
CNBC's Rick Santelli and Robert Laszewski discuss what's wrong with Obamacare.
Obamacare rates are 7 percent less in states with greater Medicaid eligibility, a new analysis says.
First rule about being bought by an advertising company: You’re probably going to end up selling advertising. Recode reports.
Elena Delle Donne nearly walked off the court for good, until she learned a valuable lesson from being overworked.
A trader has bet $2 million on a Wal-Mart rally, and Dan Nathan breaks down the trade.
As political pressure appears to mount on biotech stocks, some technical analysts say the foundation for a bounce may be building.
"Monetary policy is thwarting goals to strengthen the economy and to make banks safer by now," John Cryan says.
CNBC's Meg Tirrell reports the latest on the drug price debate, Teva on a generic EpiPen and the FDA. David Maris, Wells Fargo analyst, and the "FMHR" traders weigh in.
Fiber, like the "Other Bets" businesses outside of Google, is facing ongoing scrutiny about its operations. Recode reports.